Jazz Pharmaceuticals Plc (JAZZ) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Neurocrine Biosciences, Inc.

Alnylam Pharmaceuticals, Inc.

Incyte Corp.

Jazz Pharmaceuticals Plc

Viatris, Inc.

Royalty Pharma Plc

United Therapeutics Corp.

Repligen Corp.

Sarepta Therapeutics, Inc.

Walgreens Boots Alliance, Inc.

Roivant Sciences Ltd.

Why is Jazz Pharmaceuticals Plc ?

Healthy long term growth as Net Sales has grown by an annual rate of 12.54%

With a growth in Operating Profit of 333.71%, the company declared Very Positive results in Mar 26

The company has declared positive results for the last 3 consecutive quarters
NET PROFIT(Q) At USD 301.43 MM has Grown at 398.01%
INVENTORY TURNOVER RATIO(HY) Highest at 2.59 times
RAW MATERIAL COST(Y) Fallen by -0.27% (YoY)

With ROCE of 7.99%, it has a fair valuation with a 1.96 Enterprise value to Capital Employed

The stock is trading at a discount compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of 115.67%, its profits have risen by 9.7% ; the PEG ratio of the company is 1.9

High Institutional Holdings at 100%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.

Market Beating performance in long term as well as near term

Along with generating 115.67% returns in the last 1 year, the stock has outperformed S&P 500 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you buy?

Overall Portfolio exposure to Jazz Pharmaceuticals Plc should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Jazz Pharmaceuticals Plc for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Jazz Pharmaceuticals Plc

115.67%

2.93

37.95%

S&P 500

22.24%

1.67

13.28%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

12.54%

EBIT Growth (5y)

-5.43%

EBIT to Interest (avg)

2.75

Debt to EBITDA (avg)

2.97

Net Debt to Equity (avg)

0.67

Sales to Capital Employed (avg)

0.42

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

9.96%

ROE (avg)

10.20%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.60

EV to EBIT

24.48

EV to EBITDA

11.12

EV to Capital Employed

1.96

EV to Sales

3.32

PEG Ratio

1.93

Dividend Yield

ROCE (Latest)

7.99%

ROE (Latest)

14.85%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Bullish

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

21What is working for the Company

NET PROFIT(Q)

At USD 301.43 MM has Grown at 398.01%

INVENTORY TURNOVER RATIO(HY)

Highest at 2.59 times

RAW MATERIAL COST(Y)

Fallen by -0.27% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at 56.1 %

PRE-TAX PROFIT(Q)

Highest at USD 307.7 MM

EPS(Q)

Highest at USD 4.43

0What is not working for the Company

NO KEY NEGATIVE TRIGGERS

Here's what is working for Jazz Pharmaceuticals Plc

Pre-Tax Profit

At USD 307.7 MM has Grown at 359.84%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (USD MM)

Net Profit

At USD 301.43 MM has Grown at 398.01%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (USD MM)

Inventory Turnover Ratio

Highest at 2.59 times and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Pre-Tax Profit

Highest at USD 307.7 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

EPS

Highest at USD 4.43

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Debt-Equity Ratio

Lowest at 56.1 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost

Fallen by -0.27% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation

Highest at USD 181.4 MM

in the last five periods

MOJO Watch

The expenditure on assets done by the company may have gone into operation

Depreciation (USD MM)